drugset / Trial / NCT02359032

A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects

NCT02359032 ↗

Phase 1 Completed 88 enrolled Astellas Pharma Europe B.V.
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is evaluate the safety and tolerability of single and multiple ascending oral doses of ASP6858. This study will also evaluate the pharmacokinetics (PK) of ASP6858 and its metabolites as well as the effect of food to the PK of ASP6858. The study will also evaluate the pharmacodynamics of ASP6858.

Timeline

Start
2015-01
Primary completion
2016-01
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ASP6858 Unknown — Oral

Indications

No indication recorded.